^
    Back
    Association details:
    Biomarker:TNFRSF8 positive
    Cancer:Lymphoma
    Drug Class:T-lymphocyte cell therapy
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    Front Cell Dev Biol
    Title:

    Humanized CD30-Targeted Chimeric Antigen Receptor T Cells Exhibit Potent Preclinical Activity Against Hodgkin's Lymphoma Cells

    Published date:
    01/12/2022
    Excerpt:
    In this study, humanized scFvs were utilized to construct a CD30-directed CAR (hHRS3-CAR), and its effectiveness was compared with that of HRS3-CAR. The hHRS3-CAR-T cells specifically kill CD30-positive tumor cell lines in vitro and eliminate lymphoma xenografts in immunodeficient mice with comparable efficiency to HRS3-CAR.
    DOI:
    10.3389/fcell.2021.775599